Integra LifeSciences Holdings Corporation

NASDAQ:IART

Medical - Devices

Healthcare
$13.86 +4.71%

+$0.81 today

Market cap
$1.08B
Beta
1.25
P/E (TTM)
-2.8
EPS (TTM)
-$6.44
52W Low $8.70High $18.26

Volume 0.58M

Average 0.96M

IART Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Integra LifeSciences Holdings CorporationNASDAQ: IART

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents broadly unchanged from a year ago

Cash & equivalents stood at $236.81M at the end of Q1 FY2026, down 1.0% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at -19.9% a year.

Context

  • Cash & equivalents amounted to 6.6% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -1.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$236.81M+0.7% QoQ
Last fiscal yearDec 2025
$235.05M-4.6% YoY
Year agoMar 2025
$239.1M-1.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.0%——
1 year-4.6%——
3-year CAGR-19.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
235.05M USD
Year-over-year change
-4.6%
4-year CAGR
-17.7%

Cash & Equivalents vs competitors

How IART compares with its peers on the latest reported figures

  • IART's Mar 2026 cash & equivalents of $236.81M is the 5th highest of the 11 companies compared; the peer median is $130.1M.
  • Its year-over-year change of -1.0% is the 7th highest of 11, against a peer median of +45.4%.
  • Cash & equivalents amounts to 6.6% of total assets for IART, versus a peer median of 11.4%.
IART Competitors Peer median
Cash & Equivalents for IART and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SYKStryker CorporationJun 2026$3.39B +42.8%+29.6%7.1%
SNNSmith & Nephew plcDec 2025$557M -10.0%+16.8%5.3%
GMEDGlobus Medical, Inc.Jun 2026$507.75M +121.3%+51.8%9.3%
AXGNAxoGen, Inc.Sep 2026$328.89M +1276.0%+32.5%59.8%
IARTIntegra LifeSciences Holdings CorporationMar 2026$236.81M -1.0%-19.9%6.6%
ATECAlphatec Holdings, Inc.Mar 2026$139.91M -8.7%+23.8%17.5%
OFIXOrthofix Medical Inc.Mar 2026$120.28M +107.5%+17.4%13.6%
AORTArtivion, Inc.Mar 2026$55.76M +47.9%+18.2%6.3%
CNMDCONMED CorporationMar 2026$35.03M -1.3%+12.1%1.5%
TELATELA Bio, Inc.Jun 2026$30.42M -13.0%+6.6%50.9%
XTNTXtant Medical Holdings, Inc.Mar 2026$12.16M +141.6%-5.6%15.6%
Peer median (excluding IART) $130.1M+45.4%+17.8%11.4%

Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents513.45M456.66M276.4M246.38M235.05M
Short-term Investments0032.69M27.19M28.69M
Net Receivables243.24M263.47M259.33M272.37M278.85M
Inventory317.39M324.58M389.61M429.09M492.74M
Other Current Assets13.82M31.03M32.64M29.65M28.13M
Total Current Assets1.15B1.16B1.06B1.08B1.16B
Property, Plant & Equipment (Net)396.25M459.59M496.38M549.77M584.9M
Goodwill1.01B1.04B1.06B1.1B615.16M
Intangible Assets1.15B1.13B1.07B1.21B1.13B
Long-term Investments6.48M567.34M30.71M38.3M12.78M
Tax Assets56.95M45.99M46.08M34.92M69.85M
Other Non-current Assets9.96M(510.15M)27.48M28.21M25.1M
Total Non-current Assets2.63B2.73B2.72B2.96B2.44B
Total Assets3.78B3.89B3.78B4.04B3.6B
Account Payables61.84M102.1M92.33M82.5M95.73M
Short-term Debt59.78M52.75M14.53M607.08M126.55M
Tax Payables00003.65M
Deferred Revenue5.3M7.25M8.54M10.48M11.46M
Other Current Liabilities105.68M65.41M100.84M37.79M74.08M
Total Current Liabilities340.02M320.91M306.98M922.13M455.98M
Long-term Debt1.5B1.41B1.49B1.2B1.73B
Deferred Tax Liabilities45.79M63.34M35.32M60.83M5.66M
Deferred Revenue (Non-current)6.7M8.8M7.7M9.2M0
Other Non-current Liabilities120.26M138.5M192.24M137.04M204.28M
Total Non-current Liabilities1.76B1.76B1.89B1.57B2.1B
Total Liabilities2.1B2.09B2.19B2.49B2.56B
Common Stock896K905K909K916K923K
Retained Earnings698.57M879.12M946.86M939.92M423.44M
Accumulated OCI(45.16M)10.27M(15.11M)(27.57M)(30.08M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.68B1.8B1.59B1.55B1.04B
Total Debt1.67B1.63B1.68B1.98B2.03B
Net Debt1.15B1.17B1.41B1.74B1.8B

Integra LifeSciences Holdings Corporation

NASDAQ:IART

Intrinsic Alpha fair value

Locked

Current Price

$13.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.